INTRODUCTION

Preapheresis peripheral blood (PB) CD34
1 cell count is a strong predictor of hematopoietic stem cell (HSC) mobilization and collection success in patients with multiple myeloma (MM) [1] [2] [3] [4] . Routine monitoring of PB CD34
1 cell numbers is standard practice to optimize the timing, cost, and success of HSC collection after mobilization [1, 5] . Despite routine use, however, a uniform cell count of circulating CD34
1 cells to predict the success of mobilization has not yet been established [1] [2] [3] [4] [5] [6] .
Various CD34
1 cell count values, ranging from 5 cells/mL to 15 cells/mL, have been used in studies to identify patients at risk for mobilization failure [2, 3, 6] , and a PB CD34
1 cell count of 20 cells/mL has been used to initiate HSC collection with a high rate of success [4, [7] [8] [9] . In one study, however, only 54% to 58% of patients who were mobilized with granulocyte-colony stimulating factor (G-CSF) or G-CSF plus chemotherapy had a preapheresis PB CD34
1 cell count $20 cells/mL [8] . Thus, a substantial proportion of patients remain likely to experience suboptimal HSC collection yields.
Plerixafor is a bicyclam molecule that blocks the binding of stromal cell-derived factor-1a to the CXCR4 chemokine receptor [10, 11] , resulting in elevated levels of circulating HSCs in humans and animal models [12, 13] . Plerixafor, in combination with G-CSF, is currently approved in the United States for mobilization of HSCs for collection and subsequent autologous stem cell transplantation (ASCT) in patients with non-Hodgkin lymphoma or MM [14] . The safety and efficacy of plerixafor plus G-CSF in front-line mobilization of HSCs in patients with MM has been demonstrated in a phase 3, randomized, placebo-controlled study (Study 3102) [15] . In that study, a significantly higher percentage of patients treated with plerixafor plus G-CSF achieved optimal CD34 1 stem cell yields for ASCT in fewer apheresis days compared with patients treated with placebo plus G-CSF. Transplantation outcomes for the plerixafor-treated patients (n 5 142; 95.9%) and placebo-treated patients (n 5 136; 88.3%) who proceeded to ASCT were similar in the 2 groups, with 99.3% of plerixafor-treated patients and 100% of placebo-treated patients achieving neutrophil engraftment. In addition, a total of 99.3% of patients in each treatment group experienced successful platelet engraftment [15] .
Patients with a low PB CD34 1 cell count (\20 cells/mL) are generally considered ''poor'' mobilizers. The purpose of this post hoc analysis was to evaluate the efficacy of plerixafor plus G-CSF compared with placebo plus G-CSF in the mobilization of HSCs in patients with MM who have low preapheresis PB CD34 1 cell counts.
METHODS
Study Design
This study was a post hoc analysis of data obtained from a prospective, randomized, double-blind, placebo-controlled, phase 3 clinical trial that compared the safety and efficacy of plerixafor (0.24 mg/kg/day s.c.) plus G-CSF (10 mg/kg/day) and placebo plus G-CSF for HSC mobilization and autologous HSC transplantation (HSCT) in patients with MM [15] . Institutional Review Board approval was obtained at each site in the original study. Because no new information was collected for the post hoc analysis, separate Institutional Review Board approval was not requested.
Patients with available data on PB CD34 1 cell counts on both day 4 and day 5 were included in this analysis ( Figure 1 ). In accordance with clinical practice, the patients were divided into 4 groups based on baseline PB CD34 1 cell count on day 4: \10 cells/mL, \15 cells/mL, \20 cells/mL, and $20 cells/mL. Endpoints for this post hoc analysis were the fold-increase in PB CD34 1 cells; the proportion of patients achieving the minimum ($2 Â 10 6 CD34 1 cells/kg) and optimum ($6 Â 10 6 CD34 1 cells/kg) cell doses at days 1, 2, 3, and 4 of apheresis; apheresis yields; patients proceeding to HSCT; and time to engraftment. Comparisons were made between the plerixafor and placebo groups stratified by day 4 PB CD34 1 cell count.
Patient Eligibility
Patients enrolled in the 3102 Study were aged 18 to 78 years with biopsy-confirmed MM in first or second complete or partial remission. Eligibility criteria were $4 weeks since the last cycle of chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, WBC count .2.5 Â 10 9 cells/L, absolute neutrophil count .1.5 Â 10 9 cells/L, platelet count .100 Â 10 9 cells/L, serum creatinine #2.2 mg/dL, normal liver function, and normal cardiac and pulmonary status. Exclusion criteria were previous autologous or allogeneic HSCT, failed previous HSC collection attempt, receipt of G-CSF within 14 days of the first dose of G-CSF on the study, receipt of bone-seeking radionuclides or radiation therapy to $50% of the pelvis, and receipt of thalidomide, lenalidomide, dexamethasone, or bortezomib within 7 days of the first dose of G-CSF on the study.
Mobilization and Transplantation
Patients underwent mobilization with G-CSF each morning for up to 8 days. Beginning on the evening of day 4, patients received either plerixafor or placebo (s.c.) daily for up to 4 days or until $6 Â 10 6 CD34 1 cells/kg were collected. Apheresis (3.0 blood volume 6 10%) began on day 5 and was continued daily for up to 4 days or until $6 Â 10 6 CD34
1 cells/kg were collected ( Figure 1 ). HSCT using collected CD34 1 cells (minimum 2 Â 10 6 cells/kg) was performed within 5 weeks of the last apheresis.
PB CD34
1 Cell Enumeration 
Engraftment Criteria
Neutrophil engraftment was defined as a neutrophil count $0.5 Â 10 9 cells/L for 3 days or $1.0 Â 10 9 cells/ L for 1 day. Platelet engraftment was defined as a platelet count $20 Â 10 9 cells/L without a transfusion for the preceding 7 days. For patients undergoing multiple HSCTs, engraftment was reported for the first transplantation only.
Statistical Analysis
P values were calculated using Wilcoxon's ranksum test. For continuous outcomes and the c 2 test for dichotomous outcomes. A P value of \.05 was considered to indicate statistical significance. All analyses were performed using SAS version 8.2 or later (SAS Institute, Cary, NC).
RESULTS
Patients
In the 3102 Study, a total of 302 patients were randomized to receive plerixafor plus G-CSF (n 5 148) or placebo plus G-CSF (n 5 154) [15] . Patients with available PB CD34 1 cell count data on day 4 were included in this post hoc analysis (plerixafor group, n 5 129 [87.2%]; placebo group n 5 129 [83.8%]). Patients were classified by day-4 cell count into the following groups: \10 cells/mL, \15 cells/mL, \20 cells/ mL, and $20 cells/mL. Patient baseline characteristics and demographic data are summarized in Table 1 . There were no significant differences between the plerixafor and placebo groups with respect to baseline characteristics, regardless of cell count group.
Efficacy
PB CD34
1 counts
Median absolute PB CD34 1 cell counts on day 4 were comparable between the plerixafor-treated and placebo-treated patients in each cell count group (Table 2) . However, the median PB CD34
1 cell count on day 5 was significantly greater in the plerixafortreated patients across all cell count groups (\10: 48.5 versus 11.6 cells/mL; \15: 52.1 versus 18.0 cells/mL; \20: 66.0 versus 20.2 cells/mL; $20: 149.7 versus 55.5 cells/mL; P \ .001 for the plerixafor versus placebo comparison in each cell count group) ( Table 2 ). The median fold increase in PB CD34 1 cell counts between day 4 and day 5 was significantly in the plerixafor-treated patients across all cell count groups (\10: 9.6-fold versus 2.0-fold; \15: 7.7-fold versus 2.0-fold; \20: 6.6-fold versus 2.0-fold; $20: 4.1-fold versus 1.4-fold) (P \ .001) ( Table 2) .
CD34
1 stem cell collection
In nearly every comparison between the plerixafor and placebo groups across cell count groups, a significantly greater proportion of plerixafor-treated patients collected the minimum ($2 Â 10 6 CD34 1 cells/kg) and optimum ($6 Â 10 6 CD34 1 cells/kg) cell doses in 1, 2, 3, and 4 days of apheresis (minimum: P 5 not significant for plerixafor versus placebo in the $20 cells/mL group on days 2, 3, and 4; all other comparisons were significant; optimum: P 5 not significant for plerixafor versus placebo in the \10 cells/mL group on day 1 and in the \10 cells/mL and\15 cells/mL groups on day 4; all other comparisons were significant) (Figures 2 and 3) . Moreover, significantly higher median cumulative CD34
1 cell yields were collected in the patients in the plerixafor group across all cell count groups on each day of apheresis (4- apheresis compared with those in the placebo group, regardless of cell count group (Table 3) . For example, plerixafor-treated patients in the \20 cells/mL cell count group collected the minimum cell dose at a median of 1 day, compared with 2 days in placebotreated patients in this cell count group (P \ .001). Likewise, patients in the plerixafor group collected the optimum cell dose at a median of 2 days, compared with 3 days for patients in the placebo group (P\.001).
Transplantation and engraftment
Across all cell count groups, the proportion of patients proceeding to HSCT was similar in the plerixafor and placebo groups (plerixafor, 97.5%-100%; placebo, 93.3%-98.6%). The median times to neutrophil engraftment (11 days) and platelet engraftment (18-20 days) after first HSCT were similar in the 2 groups across all cell count groups. A total of 28 plerixafor-treated patients (21.7%) and 26 placebotreated patients (20.2%) underwent a second HSCT.
DISCUSSION
In this post hoc analyses, stratification of patients by PB CD34
1 cell count before apheresis revealed that 116 of the 258 patients (45.0%) had a preapheresis PB CD34
1 cell count \20 cells/mL, classifying them as potential ''slow'' or ''poor'' mobilizers. Our findings demonstrate that compared with placebo plus G-CSF, the use of plerixafor plus G-CSF significantly improved the likelihood of successful HSC collection within 4 days in all cell count groups of ''poor'' mobilizers. However, because the \15 cells/mL and \20 cells/mL cell count groups analyzed contained a significant number of patients from the \10 cells/mL group, we are unable to draw conclusions for patients whose day-4 counts fell between 10 and 19 cells/mL. Nonetheless, the advantage of plerixafor plus G-CSF for the poorest of the poor mobilizers (ie, those in the \10 cells/mL group) is significant and remains so even when their numbers are diluted by the addition of patients whose day-4 counts fell into intermediately poor ranges (those between 10 and 19 cells/mL, represented by the \15 and \20 cells/mL cell count groups). A significantly higher proportion of the slow mobilizers in the plerixafor group achieved minimum and optimum HSC collection on all 4 days of apheresis. Reciprocally, the median time to collection of the minimum and optimum HSC yields was significantly shorter in the plerixafor group (Table 3 ). These findings demonstrate that plerixafor can improve HSC collection and mobilization in poor mobilizers, beginning as early as day 1 of apheresis. Our findings also demonstrate that plerixafor plus G-CSF significantly improves the likelihood of optimum HSC collection in patients with adequate 
preapheresis PB CD34
1 cell counts ($20 cells/mL). Similar to the results in poor mobilizers, a significantly higher proportion of patients in the plerixafor group with a preapheresis CD34 1 count $20 cells/mL achieved optimum HSC collection at days 1, 2, 3, and 4 of apheresis and had significantly higher HSC yields on each apheresis day, resulting in significantly fewer days of apheresis to achieve optimum HSC collection yields. Collectively, these results indicate that plerixafor can predictably improve HSC mobilization and collection in both patients with a low preapheresis PB CD34
1 cell count (\20 cells/mL) and those with a high preapheresis PB CD34 1 cell count ($20 cells/ mL). Consistent with previous reports, the magnitude of the increase in PB CD34
1 cells was at least 3-fold greater in the plerixafor group compared with the placebo group across all cell count groups and was more pronounced in the patients with lower preapheresis PB CD34 1 cell counts. An important finding of this study is that more than 80% of the plerixafor-treated patients in each cell count group collected the minimal transplantable stem cell dose on the first day of apheresis. Additional analyses revealed a strong positive correlation between median stem cell collection on day 1 of apheresis and median total stem cell collection in both the plerixafor and placebo groups (plerixafor: r 5 0.90, P \ .0001; placebo: r 5 0.73, P \ .0001) [16] . The median CD34
1 cell count collected on day 1 was higher in the plerixafor group (7.01 Â 10 6 cells/kg versus 2.29 Â 10 6 cells/kg; P \ .001), which translated into better overall collection in the plerixafor group (10.96 Â 10 6 cells/kg versus 6.18 Â 10 6 cells/kg; P \ .001). In both the plerixafor and placebo groups, a negative correlation was found between the median CD34 1 cell collection on day 1 and the median number of apheresis days needed to collect the minimum (P \ .001) and optimum (P \ .001) CD34
1 cell doses. Consequently, better day-1 collection in the plerixafortreated patients resulted in significantly fewer apheresis days needed to achieve the target collection.
The efficacy of plerixafor in eliciting higher yields in HSC collection is an important aspect of MM disease management, given that measures of optimal engraftment have been shown to be directly related to the number of CD34 1 cells infused [17, 18] . Thus, the ability to collect the optimal stem cell dose ($6 Â 10 6 CD34 1 cells/kg) rather than the minimum dose ($2 Â 10 6 CD34 1 cells/kg) likely would have a significant impact on patient response. In addition, the ability to collect sufficient HSCs for more than one transplantation procedure may allow patients to undergo tandem HSCT, which has been shown to confer a survival advantage in patients who do not achieve a very good partial or complete response after one transplantation [19, 20] . In addition, the collection of sufficient HSCs may allow for a second transplantation as part of second-line therapy after relapse [21] . Failure rates for current mobilization regimens reported in the literature vary; however, in one of the largest studies of its kind, Pusic et al. [8] found that 26.8% of patients who received G-CSF alone collected an optimum cell dose (defined as 5 Â 10 6 cells/ kg) after 5 days of apheresis. In our analysis, in patients with a low PB CD34 1 cell count (\20 cells/mL) treated with placebo plus G-CSF, the median total yields were short of optimum (Figure 4) , with 36.7% of patients collecting the optimum cell dose, thereby precluding tandem HSCT in the majority of these patients. The addition of plerixafor to G-CSF successfully raised the median total stem cell yields in patients with a preapheresis cell count \20 cells/mL and increased their likelihood of achieving the optimum cell dose (62.5%), making them eligible for tandem HSCT if warranted. A similar advantage of plerixafor plus G-CSF in achieving the optimum stem cell dose was demonstrated in the 3102 Study, which found that treatment with plerixafor plus G-CSF resulted in 37.2% more patients achieving an optimal CD34 1 cell count (defined as 6 Â 10 6 cells/kg) in 2 or fewer apheresis days (71.6% in the plerixafor plus G-CSF group versus 34.4% in the placebo plus G-CSF group) [15] . Although no safety analyses for the specific subsets of patients have been performed, the cumulative safety data for patients in the randomized 3102 Study show a similar overall incidence of adverse events in the plerixafor and placebo groups. The most common plerixafor-related adverse events were mild to moderate gastrointestinal and injection site reactions [15] .
At this time, the International Myeloma Working Group acknowledges the potential for plerixafor to positively affect HSC collection strategies but has not made recommendations for its standard use in patients with MM [22, 23] . The International Myeloma Working Group has suggested that health economics or cost analyses are needed before the routine use of plerixafor can be recommended [22, 23] . Shaughnessy et al. [24] , in a retrospective economic analysis comparing patients mobilized using plerixafor plus G-CSF with matched historical controls mobilized with cyclophosphamide plus G-CSF, found no significant difference in mean or median cost of mobilization; the acquisition cost of plerixafor was offset primarily by the increased G-CSF use in the cyclophosphamide plus G-CSF group. Furthermore, no patient in the plerixafor plus G-CSF group required a weekend apheresis procedure, compared with 48% of patients in the control group. That study used Centers for Medicare and Medicaid reimbursement rates to compare costs, and was not able to adjust for cost differentials that might be associated with weekend apheresis [24] . Costa et al. [25] have developed an algorithm to guide plerixafor use based on both PB CD34 1 cell counts and an analysis of financial charges and including the desired target apheresis yield. In this algorithm, lower PB CD34
1 cell counts predicted a financial advantage with the addition of plerixafor to the mobilization regimen on day 4 and beyond [25] . Extending those findings, our analysis suggests that all patients with a PB CD34 1 cell cutoff of\20 cells/mL should receive plerixafor, because the probability of failing to achieve the minimal cell dose in 1 or 2 days of apheresis is $60% and $33%, respectively, with G-CSF alone, compared with only $18% and $5% with plerixafor plus G-CSF. As previously noted, collection of $6 Â 10 6 CD34 1 cells/kg has been advocated for tandem HSCT and for second HSCT at the time of relapse. If the goal is to collect $6 million cells in as few procedures as required, then adding plerixafor in patients with higher PB CD34 1 cell counts ($20 cells/ mL) may be an important therapeutic option, given that this target was achieved in 86% of patients in the plerixafor group in 2 days of apheresis, compared with $55% of those in the placebo group.
Limitations of this study include its retrospective nature and the potential for significant variation in PB CD34
1 cell count measurements among laboratories. In addition, the study did not include G-CSF plus chemotherapy as a comparative arm; however, this is because the benefits of adding chemotherapy remain controversial in patients with MM, and currently, there are no approved chemotherapeutic agents for mobilization.
Taken together, our findings support the use of up-front plerixafor in patients with MM regardless of PB CD34
1 cell count, to increase the number of circulating CD34
1 cells and improve the likelihood of obtaining minimal and optimal HSC yields for ASCT in just a few days of apheresis. These findings can provide guidance in developing institutional algorithms for future stem cell mobilization.
